Cost‑effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non‑Muscle Invasive Bladder Cancer patients (NMIBC) in Italy
DOI:
https://doi.org/10.7175/fe.v15i3.944Keywords:
Cost‑effectiveness, Hexvix®, Cystoscopy, NMIBCAbstract
OBJECTIVE: To estimate the incremental cost‑effectiveness of hexaminolevulinate (Hexvix®) + Blue Light (H+BL) cystoscopy (compared to white light cystoscopy only) when used at initial transurethral resection of the bladder tumour (TURBT) for patients diagnosed with non‑muscle invasive bladder cancer (NMIBC) in Italy.
METHODS: A cost‑effectiveness model has been developed to estimate the incremental cost‑effectiveness of introducing H+BL at initial TURBT for patients diagnosed with NMIBC in Italy. The model consists of two parts: 1) a short term decision tree which estimates the outcome of the initial diagnostic procedure, and 2) a Markov cohort model which is used to estimate long term outcomes through extrapolation based on data and assumptions about patient management, the natural history of the disease and the empirical efficacy of H+BL in improving diagnosis detection and reducing recurrence. Cost‑effectiveness results are expressed as incremental costs per QALY gained. Univariate and probabilistic sensitivity analyses are conducted to test the robustness of the model to changes in inputs and assumptions.
RESULTS: Base case results suggest that Hexvix® is a dominant strategy when used in the resection of NMIBC. Hexvix® is expected to be associated with 0.070 incremental QALYs, with cost savings of € 435 per patient. Sensitivity analyses suggest that the cost of Hexvix® and the relative risk of recurrence in intermediate and low risk groups are key drivers in the model. Probabilistic analyses indicate that Hexvix® is expected to be cost‑effective in >99% of iterations, assuming a willingness to pay threshold of € 25,000 per QALY.
CONCLUSION: In conclusion, Hexvix® is expected to be a cost‑effective strategy when used in the resection of NMIBC in Italy.
References
Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010; 14: 1-331; http://dx.doi.org/10.3310/hta14040
Malmström PU, Hedelin H, Thomas YK, et al. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009; 43: 192-8; http://dx.doi.org/10.1080/00365590902808541
Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64: 639-53; http://dx.doi.org/10.1016/j.eururo.2013.06.003
WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence worldwide in 2012. Available at http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
AIOM-AIRTUM. I numeri del cancro in Italia 2013. Available at http://www.registri-tumori.it/cms/it/node/2888
AIRTUM-ITACAN: Tumori in Italia, Versione 2.0. Associazione Italiana dei Registri Tumori. Available at http://www.registri-tumori.it
Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-45; http://dx.doi.org/10.1001/jama.2011.1142
AIOM. Linee guida Carcinoma della vescica. Edizione 2013
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with Stage Ta T1 bladder cancer using EORTC Risk tables. Eur Urol 2006; 49: 466-5; discussion 475-7
Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-4; http://dx.doi.org/10.1016/S0022-5347(05)67280-1
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75
Fradet Y, Grossman HB, Gomella L, et al.; PC B302/01 Study Group. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68-73; http://dx.doi.org/10.1016/j.juro.2007.03.028
Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 1907-13; http://dx.doi.org/10.1016/j.juro.2010.06.148
Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862-6; http://dx.doi.org/10.1097/01.ju.0000169257.19841.2a
Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012; 188: 58-62; http://dx.doi.org/10.1016/j.juro.2012.03.007
Expert Opinion of Prof. Giario Conti, director of Urology Division at Sant’Anna Hospital, Como
Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013; 64: 846-54; http://dx.doi.org/10.1016/j.eururo.2013.03.059
Demo Istat.it. Available at http://demo.istat.it/index.html
von der Maase H, Sengelov L, Roberts JT, et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, cinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8; http://dx.doi.org/10.1200/JCO.2005.07.757
EQ-5D™. Available at http://www.euroqol.org/
Kulkarni GS, Finelli A, Fleshner NE, et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007; 4: e284; http://dx.doi.org/10.1371/journal.pmed.0040284
NHS reference costs guidance for 2011-2012. Available at https://www.gov.uk/government/publications/reference-costs-guidance-for-2011-12
KARL STORZ Gmbh&Co. Data
NHS Technology Adoption Centre (NTAC). The Cost Impact of Implementing Photodynamic Diagnosis of Non-Muscle Invasive Bladder Cancer in England. Final Report, 2011
Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari. PharmacoEconomics. Italian Research Articles 2009; 11: 83-93
Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34; http://dx.doi.org/10.1016/j.urology.2005.07.062
Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Lyon: IARC Publications, 2002
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108; http://dx.doi.org/10.3322/canjclin.55.2.74
Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27: 295-300; http://dx.doi.org/10.1007/s00345-009-0395-z
Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010; 57: 607-14; http://dx.doi.org/10.1016/j.eururo.2010.01.025
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
